In this study, we show that WEE1 inhibition can sensitise BRCA1/2 wild-type TNBC to PARP inhibitors resulting in synergistic anti-tumour efficacy with increased DNA damage, apoptosis, replication stress, and STING pathway activation. The gene discussed is WEE1; the disease is neoplasm.